NAUT vs QBTS vs IONQ vs CDNA

For growth investors, IonQ, Inc.

(IONQ) is the stronger pick with 201. 9% revenue growth year-over-year, versus 13. 8% for CareDx, Inc (CDNA). Analysts rate Nautilus Biotechnology, Inc. (NAUT) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, IonQ, Inc.

(IONQ) delivered a total return of +367. 1%, compared to -72. 4% for CareDx, Inc (CDNA). Over 10 years, the gap is even starker: CDNA returned +385. 1% versus NAUT's -72. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CareDx, Inc (CDNA) is the lower-risk stock at 1.

39β versus D-Wave Quantum Inc. 's 3. 48β — meaning QBTS is approximately 150% more volatile than CDNA relative to the S&P 500. On balance sheet safety, IonQ, Inc. (IONQ) carries a lower debt/equity ratio of 1% versus 19% for Nautilus Biotechnology, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), IonQ, Inc.

(IONQ) is pulling ahead at 201. 9% versus 13. 8% for CareDx, Inc (CDNA). On earnings-per-share growth, the picture is similar: Nautilus Biotechnology, Inc. grew EPS 16. 1% year-over-year, compared to -143. 0% for CareDx, Inc. Over a 3-year CAGR, IONQ leads at 126. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Nautilus Biotechnology, Inc.

(NAUT) is the more profitable company, earning 0. 0% net margin versus -1444. 1% for D-Wave Quantum Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NAUT leads at 0. 0% versus -487. 4% for IONQ. At the gross margin level — before operating expenses — QBTS leads at 82. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for QBTS: 76.

8% to $38. 89.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, CareDx, Inc (CDNA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+385.

1% 10Y return). D-Wave Quantum Inc. (QBTS) carries a higher beta of 3. 48 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CDNA: +385. 1%, QBTS: +116. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NAUT (Healthcare) and QBTS (Technology) and IONQ (Technology) and CDNA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NAUT is a small-cap quality compounder stock; QBTS is a small-cap high-growth stock; IONQ is a mid-cap high-growth stock; CDNA is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.